If your gastroenterologist has prescribed Tremfya for Crohn's disease and you have a Cigna plan, the practical question is whether Cigna will pay for it and what you have to do first. Tremfya, the brand name for guselkumab, is an interleukin-23 antagonist that the FDA approved for moderately to severely active Crohn's disease in March 2025. Because the Crohn's indication is so new, many Cigna members find little plan-specific guidance about it. The short answer is that Cigna does cover Tremfya for Crohn's, but coverage runs through prior authorization, a specialty pharmacy, and formulary rules that vary by plan. Understanding how those pieces fit together helps you avoid surprise denials.
How Cigna handles a specialty biologic like Tremfya
Cigna manages most prescription drug benefits through Express Scripts, its pharmacy benefit manager, and dispenses specialty biologics through Accredo, its specialty pharmacy. Both Express Scripts and Accredo sit inside Cigna's health services arm, Evernorth. For a member, this means a Tremfya prescription does not simply go to a retail counter. It is reviewed for prior authorization, then typically filled and shipped by Accredo, which also coordinates the clinical support that comes with complex specialty therapies. Tremfya offers a fully subcutaneous regimen as well as an intravenous induction option, so a self-injected prescription usually sits on the pharmacy benefit, while an infusion may be billed under the medical benefit depending on your plan.
What Cigna's coverage policy typically requires
Cigna publishes its own coverage position criteria, and Tremfya for Crohn's is now listed in the Inflammatory Conditions Tremfya Subcutaneous Prior Authorization Policy. Prior authorization is recommended for prescription benefit coverage. Under that published policy, initial approval for Crohn's runs for six months when the patient is at least 18 years old and the medication is prescribed by or in consultation with a gastroenterologist. The policy notes that current ACG and AGA 2025 Crohn's guidelines recommend upfront use of advanced therapies rather than strict step-up therapy, and it lists TNF inhibitors, vedolizumab, IL-23 inhibitors, and upadacitinib among recommended options. Even so, your specific plan can layer on formulary step therapy that prefers another product first. Always read your own plan documents to confirm.
Why step therapy and prior-product failures still come up
Although Cigna's national coverage policy for subcutaneous Tremfya does not, by itself, require failing an anti-TNF first, individual plan formularies frequently place newer biologics on a specialty tier with step therapy attached. In practice that often means trying and failing a preferred agent, commonly a tumor necrosis factor inhibitor such as a Humira product, before a payer approves a later-line drug. Documenting prior therapy clearly strengthens any request. Useful records to gather include the following.
Names and dates of prior biologics or conventional therapies and why each was stopped
Objective measures of active disease such as fecal calprotectin, C-reactive protein, or endoscopy
Your gastroenterologist's clinical rationale for choosing Tremfya now
These align with the objective measures Cigna cites when it reviews whether a continuing patient is responding to therapy.
The clinical case behind a later-line approval
The evidence supporting Tremfya in Crohn's gives prescribers a strong medical-necessity argument. In the phase 3 GALAXI-2 and GALAXI-3 trials, intravenous guselkumab induction followed by subcutaneous maintenance was superior to placebo for clinical response and remission, and the program also showed superiority versus ustekinumab on certain endpoints at week 48. A fully subcutaneous regimen was tested in the phase 3 GRAVITI study, where a significantly greater share of guselkumab-treated participants reached clinical remission and endoscopic response at week 12 than those on placebo. The FDA prescribing information describes intravenous induction of 200 mg at weeks 0, 4, and 8, with subcutaneous maintenance thereafter. These trial names and dosing details belong in the prior authorization packet your gastroenterologist submits.
How to verify coverage and respond to a denial
The most reliable way to confirm your benefit is to check your plan's formulary and Tremfya coverage policy directly, then call the member services number on your card. Ask whether Tremfya is covered for Crohn's, what tier it sits on, and whether step therapy applies before approval. If Cigna denies the request, you have appeal rights, and a step-therapy denial can often be challenged with documentation that preferred drugs failed or are not appropriate for you. Cigna also reviews continuation of therapy against response criteria such as improved symptoms or reduced inflammatory markers, so tracking your own measures over time supports both initial approval and renewal.
Conclusion
Cigna does provide a coverage pathway for Tremfya in Crohn's disease, managed through Express Scripts for the pharmacy benefit and Accredo for specialty dispensing, with prior authorization as the gateway. Because the Crohn's indication arrived only in 2025, the published subcutaneous coverage policy is recent and your specific plan may add formulary step therapy on top of it. The dependable approach is to read your plan's own documents, confirm the tier and any step requirements with member services, and have your gastroenterologist build a thorough prior authorization that names the supporting trials, your disease activity, and the history of any therapies you have already tried.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.